A Phase I/II signal finding study of AEVI-002 in severe pediatric onset Crohn's disease.

Trial Profile

A Phase I/II signal finding study of AEVI-002 in severe pediatric onset Crohn's disease.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs AEVI 002 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 According to an Aevi Genomic Medicine media release, initial data is anticipated around year-end 2017.
    • 15 Mar 2017 New trial record
    • 09 Mar 2017 According to an Aevi Genomic Medicine media release, company anticipates announcing data from this study during second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top